Truist Securities Maintains Buy on Genmab, Raises Price Target to $53
Portfolio Pulse from Benzinga Newsdesk
Truist Securities has maintained a Buy rating on Genmab (NASDAQ:GMAB) and raised the price target from $50 to $53.
June 04, 2024 | 12:54 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Truist Securities has maintained a Buy rating on Genmab and increased the price target from $50 to $53, indicating confidence in the company's future performance.
The raised price target and maintained Buy rating from Truist Securities suggest positive sentiment and confidence in Genmab's future performance, likely leading to a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100